CA2941460C - Vesicules extracellulaires derivees d'erythrocyte comme biomarqueur d'evaluation clinique de maladie de parkinson - Google Patents

Vesicules extracellulaires derivees d'erythrocyte comme biomarqueur d'evaluation clinique de maladie de parkinson Download PDF

Info

Publication number
CA2941460C
CA2941460C CA2941460A CA2941460A CA2941460C CA 2941460 C CA2941460 C CA 2941460C CA 2941460 A CA2941460 A CA 2941460A CA 2941460 A CA2941460 A CA 2941460A CA 2941460 C CA2941460 C CA 2941460C
Authority
CA
Canada
Prior art keywords
eev
disease
subject
parkinson
blood sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2941460A
Other languages
English (en)
Other versions
CA2941460A1 (fr
Inventor
Francesca Cicchetti
Eric Boilard
Steve Lacroix
Isabelle St-Amour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
Original Assignee
Universite Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Laval filed Critical Universite Laval
Priority to CA2941460A priority Critical patent/CA2941460C/fr
Publication of CA2941460A1 publication Critical patent/CA2941460A1/fr
Application granted granted Critical
Publication of CA2941460C publication Critical patent/CA2941460C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente description concerne des procédés dévaluation clinique de la maladie de Parkinson chez un sujet à laide de vésicules extracellulaires dérivées dérythrocyte comme biomarqueur.
CA2941460A 2016-09-08 2016-09-08 Vesicules extracellulaires derivees d'erythrocyte comme biomarqueur d'evaluation clinique de maladie de parkinson Active CA2941460C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2941460A CA2941460C (fr) 2016-09-08 2016-09-08 Vesicules extracellulaires derivees d'erythrocyte comme biomarqueur d'evaluation clinique de maladie de parkinson

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2941460A CA2941460C (fr) 2016-09-08 2016-09-08 Vesicules extracellulaires derivees d'erythrocyte comme biomarqueur d'evaluation clinique de maladie de parkinson

Publications (2)

Publication Number Publication Date
CA2941460A1 CA2941460A1 (fr) 2018-03-08
CA2941460C true CA2941460C (fr) 2023-05-23

Family

ID=61557419

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2941460A Active CA2941460C (fr) 2016-09-08 2016-09-08 Vesicules extracellulaires derivees d'erythrocyte comme biomarqueur d'evaluation clinique de maladie de parkinson

Country Status (1)

Country Link
CA (1) CA2941460C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021107155A1 (fr) * 2019-11-29 2021-06-03 富士フイルム和光純薬株式会社 Procédé d'aide au diagnostic de la maladie de parkinson, biomarqueur, kit de réactifs et dispositif
CN112386679B (zh) * 2020-11-18 2023-05-30 徐州医科大学 一种包载sigma-1受体的外泌体在制备抗抑郁药物中的应用

Also Published As

Publication number Publication date
CA2941460A1 (fr) 2018-03-08

Similar Documents

Publication Publication Date Title
Shi et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease
US10914748B2 (en) Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing Parkinson's disease
US20230408532A1 (en) Erythrocyte-derived extracellular vesicles and proteins associated with such vesicles as biomarkers for parkinson's disease
Nielsen et al. A flow cytometric method for characterization of circulating cell-derived microparticles in plasma
McMillin et al. Direct measurement of free copper in serum or plasma ultrafiltrate
Cloke et al. Characterization of a novel population of low-density granulocytes associated with disease severity in HIV-1 infection
Bester et al. Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS)
Bucciarelli et al. Circulating microparticles and risk of venous thromboembolism
Musante et al. Residual urinary extracellular vesicles in ultracentrifugation supernatants after hydrostatic filtration dialysis enrichment
Petchakup et al. Label-free leukocyte sorting and impedance-based profiling for diabetes testing
Herrmann et al. Differentiating sepsis from non-infectious systemic inflammation based on microvesicle-bacteria aggregation
CA2941460C (fr) Vesicules extracellulaires derivees d'erythrocyte comme biomarqueur d'evaluation clinique de maladie de parkinson
Taha Plasma versus serum for extracellular vesicle (EV) isolation: A duel for reproducibility and accuracy for CNS‐originating EVs biomarker analysis
KR20160129444A (ko) 혈장 내 아밀로이드베타의 농도를 통해 알츠하이머병을 임상학적 및 병리학적으로 모니터링하는 방법
Siwaponanan et al. Enumeration and phenotyping of circulating microvesicles by flow cytometry and nanoparticle tracking analysis: Plasma versus serum
Pliyev et al. Circulating CD35−/CD49d+ neutrophils in influenza virus infection patients
EP3128327A1 (fr) Procédé de détection de l'expression de la protéine smn
Mazzucco et al. Assessment of regulatory T cells in childhood immune thrombocytopenic purpura
US10527634B2 (en) Diagnostic markers of cognitive impairments, kits and uses thereof
Gharishvandi et al. Assessment of Neutrophil gelatinase-associated lipocalin (NGAL) as an early biomarker for detection of renal impairment in hypertensive patients
Hesselink et al. Fragile neutrophils in surgical patients: A phenomenon associated with critical illness
Chiva-Blanch et al. Functional and cognitive decline is associated with increased endothelial cell inflammation and platelet activation: liquid biopsy of microvesicles in community-dwelling octogenarians
Ali et al. Bengal macrothrombocytopenia is not totally an innocuous condition
JP2016070798A (ja) ベーチェット病の判定を補助する方法、及びベーチェット病の活動性の評価を補助する方法
Gironi et al. Platelet glutamate uptake and Th1 cells inversely correlate in relapsing/remitting and in progressive multiple sclerosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210826

EEER Examination request

Effective date: 20210826

EEER Examination request

Effective date: 20210826

EEER Examination request

Effective date: 20210826

EEER Examination request

Effective date: 20210826

EEER Examination request

Effective date: 20210826

EEER Examination request

Effective date: 20210826

EEER Examination request

Effective date: 20210826